Breaking News

Novasep’s European Sites Pass FDA Inspections

October 22, 2013

Audits demonstrate custom manufacturing capabilities

Novasep’s European custom manufacturing sites in Le Mans, France and Leverkusen, Germany have successfully passed FDA inspections. The audits took place at the two facilities in June and July 2013.
 
The FDA audit at the Le Mans site was a pre-approval inspection for production of paclitaxel, an anticancer parenteral active ingredient. The audit demonstrates the team’s capability to handle highly potent active pharmaceutical ingredients (HPAPI), including paclitaxel. The Leverkusen facility audit included both a pre-approval inspection of the production of formulated nitroglycerine and an overall cGMP inspection on all products for the U.S. market. 
 

 
“The FDA has tightened up its surveillance and audits,” said Michel Spagnol, chief executive officer at Novasep. “Adhering to regulatory requirements is critical, although it is becoming progressively more challenging across the industry. Our teams’ commitment to quality is impressive. I am very pleased with our continued track record in securing FDA inspection approval and the added assurance these successes give our global customers.”
 

 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important